Adaptive Biotechnologies IPO

Adaptive Biotechnologies is a biotechnology company specializing immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems.

Register for Details

For more details on financing and valuation for Adaptive Biotechnologies, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Adaptive Biotechnologies's ticker symbol?


What is Adaptive Biotechnologies's stock price?

6.96 as of 5/31/23

Adaptive Biotechnologies Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
1/4/2018 Series F-1 $45MM raised $XXX.XX $XXX.XX
5/6/2015 Series F $195.1MM raised $XXX.XX $XXX.XX
1/22/2015 Series E1 $105.12MM raised $XXX.XX $XXX.XX
1/21/2015 Series E $93.75MM raised $XXX.XX $XXX.XX
7/29/2014 Series D $107MM raised $XXX.XX $XXX.XX
7/9/2013 Series C $5.02MM raised $XXX.XX $XXX.XX
6/2/2011 Series B $5.82MM raised $XXX.XX $XXX.XX
3/24/2010 Series A $4.55MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Adaptive Biotechnologies

Forge green plus iconForge green minus icon

What is Adaptive Biotechnologies funding to date?

Adaptive Biotechnologies has raised $561.37MM with the following series:
$4.55MM raised for Series A,$5.82MM raised for Series B,$5.02MM raised for Series C,$107MM raised for Series D,$93.75MM raised for Series E,$105.12MM raised for Series E1,$195.1MM raised for Series F,$45MM raised for Series F-1.
Forge green plus iconForge green minus icon

When was Adaptive Biotechnologies founded?

Adaptive Biotechnologies was founded in 2009.
Updated on: Jun 12, 2022